The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma |
| |
Authors: | Linda M. Pak,Mark A. Schattner,Vinod Balachandran,Michael I. D Angelica,Ronald P. DeMatteo,T. Peter Kingham,William R. Jarnagin,Peter J. Allen |
| |
Affiliation: | 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA;2. Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA |
| |
Abstract: | BackgroundElevation in the serum immunoglobulin-G4 (IgG4) level has been used as a diagnostic marker to distinguish autoimmune pancreatitis (AIP) from pancreatic ductal adenocarcinoma (PDAC), but its true utility is ill-defined. This study evaluates the clinical utility of IgG4 in differentiating AIP from PDAC.MethodsAll patients evaluated in the hepatopancreaticobiliary surgery clinics with measured serum IgG4 were included. Patients were divided into normal IgG4 (<135 mg/dL) and elevated IgG4 (≥135 mg/dL) groups. The final diagnosis was determined by operative pathology when available or by clinical outcome. The sensitivity, specificity, PPV, and NPV of IgG4 for diagnosing AIP was assessed.ResultsBetween 1997 and 2015, 298 patients were identified. Normal IgG4 levels were present in 85% of patients (254/298), while 15% (44/298) were elevated. The overall prevalence of AIP was 17% (52/298). The sensitivity and specificity of IgG4 for AIP was 67% and 96%, respectively; however, the PPV was only 80%, including a 9% occurrence of PDAC in patients with an elevated IgG4.ConclusionIn this study of selected patients who underwent IgG4 testing, 9% of elevated IgG4 patients had PDAC. The overreliance on IgG4 as diagnostic for AIP may lead to mis-diagnosis and delayed treatment for PDAC. |
| |
Keywords: | Correspondence: Peter J. Allen Department of Surgery Memorial Sloan Kettering Cancer Center 1275 York Ave C-896 New York NY 10065 USA. |
本文献已被 ScienceDirect 等数据库收录! |
|